Ticker: RCUS

Compañia: Arcus Biosciences Inc

Índice: NYQ

Sector: Salud

Divisa: EURUSD

Valor actual: 31.75

Descripción:

Noticias de  RCUS

Arcus Biosciences, Inc., una compañía biofarmacéutica en etapa clínica, desarrolla y comercializa terapias contra el cáncer en los Estados Unidos. Su cartera de productos incluye, Etrumadenant, un antagonista dual del receptor de adenosina A2a / A2b, que se encuentra en un ensayo clínico de fase 1b / 2; y Zimberelimab, un anticuerpo anti-PD-1 que se encuentra en un ensayo clínico de fase 1b para monoterapia. La empresa también está desarrollando Domvanalimab, un anticuerpo monoclonal anti-TIGIT, que se encuentra en fase 2 de desarrollo para el tratamiento del cáncer de pulmón de células no pequeñas metastásico de primera línea en combinación con Zimberelimab; y AB680, el inhibidor de CD73 de molécula pequeña se encuentra en un estudio de fase 1 / 1b para el tratamiento del cáncer de páncreas metastásico de primera línea. Tiene un acuerdo de colaboración para el desarrollo clínico con Strata Oncology, Inc. para evaluar Zimberelimab; una colaboración con AstraZeneca para evaluar domvanalimab, su anticuerpo anti-TIGIT en investigación, en combinación con Imfinzi (durvalumab) en un ensayo clínico de fase 3 de registro en pacientes con cáncer de pulmón de células no pequeñas en estadio III irresecable; y acuerdos de licencia con Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC y WuXi Biologics para desarrollar anticuerpos anti-CD39 para el tratamiento del cáncer. La empresa se constituyó en 2015 y tiene su sede en Hayward, California.

Noticias:

Noticias de  RCUS

Riding the Trend or Protecting Profits | Arcus Biosciences Inc. (RCUS)

Arcus Biosciences Inc. (NYSE:RCUS) went down by -5.93% from its latest closing price compared to the recent 1-year high of $49.10. The company's stock price...

News Heater | News Heater

Noticias de  RCUS

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t.

Business Wire | Business Wire

Noticias de  RCUS

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Arcus Biosciences has compelling science but not much clinical data. Gilead has taken a very strong interest in RCUS. Click here to read more about our...

Seeking Alpha | Seeking Alpha

Noticias de  RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) Expected to Announce Quarterly Sales of $8.87 Million

Analysts predict that Arcus Biosciences, Inc. (NYSE:RCUS) will post $8.87 million in sales for the current quarter, according to Zacks.

MarketBeat | MarketBeat

Noticias de  RCUS

Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration

Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced the closing of Gilead's option exercises to three programs in Arcus's clinical-stage...

Investing News Network | Investing News Network

Noticias de  RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert C. Goeltz II Sells 485 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert C. Goeltz II sold 485 shares of the firm's stock in a transaction that occurred on Thursday, December 16th.

ETF Daily News | ETF Daily News

Noticias de  RCUS

Arcus Biosciences (NYSE:RCUS) Trading Down 3.1% Following Insider Selling

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) fell 3.1% during trading on Tuesday following insider selling activity. The stock traded as low as $40.36 and...

MarketBeat | MarketBeat

Noticias de  RCUS

Why Arcus Biosciences Stock Vaulted Higher in November

Biotech stocks had a tough time in November. Arcus Biosciences stock was able to swim against the current last month, thanks to an updated collaboration...

The Motley Fool | The Motley Fool

Noticias de  RCUS

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

Shareholders in Arcus Biosciences, Inc. ( NYSE:RCUS ) may be thrilled to learn that the analysts have just delivered a...

Simply Wall St | Simply Wall St

Noticias de  RCUS

Gilead Exercises Options to Three Arcus Biosciences Programs

By Colin Kellaher Gilead Sciences Inc. and Arcus Biosciences Inc. on Thursday unveiled an expansion of their partnership, with Gilead exercising options to.

MarketWatch | MarketWatch